髄膜炎菌ワクチン市場:2030 年までの予測

出版:Market Research Future(マーケットリサーチフューチャー) 出版年月:2022年11月

Meningococcal Vaccines market research report – Forecast till 2030
髄膜炎菌ワクチン市場調査レポート:2030 年までの予測

ページ数 120
価格
シングルユーザライセンス USD4,950
エンタープライズライセンス USD7,250
種別 英文調査報告書

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

Meningococcal Vaccines market research report – Forecast till 2030

Market Overview
Meningococcal Vaccines Market size is anticipated to register a healthy CAGR of 7.29% during the review period to reach USD 5.91 billion by the end of 2030. The key factors that drive the worldwide meningococcal antibodies market are the Rising mindfulness and flood in movement immunizations and the expansion in Research and development for antibody innovation. Expanding Consideration in Public Vaccination Projects is supposed to help the development of the meningococcal antibodies market. In any case, the rigid administrative rules and item reviews are expected to hamper market development.
The rising mindfulness about meningococcal antibodies and expanding antimicrobial of a few Neisseria meningitides clonal buildings is prompting a flood in vaccination programs across the globe. For example, a few Neisseria meningitides clonal buildings, especially CC4821 and CC11, keep on showing protection from anti-microbials. Furthermore, expanding episodes of meningococcal infections, likewise, drive the market. Besides, a rising number of voyagers and the incorporation of meningococcal immunization as an obligatory prerequisite for a couple of nations are likewise driving the market.
Market Segmentation
The market segmentation of meningococcal immunizations market is as follows
By Vaccine Type
• Conjugate
• Subcapsular
• Polysaccharide
By Serotype
• MenACWY
• MenB/BC
• MenC
• MenAC
• MenA
By End-user
• Hospitals
• Research & Academic Institutes
• Others
Regional Analysis
North America ruled the worldwide meningococcal immunizations market in 2021. This is because of the presence of central members, a deeply grounded medical services foundation, ideal government drives for immunization improvement and conveyance, and an expansion in the quantity of Research and development associations. Moreover, adolescents, teens, and youthful grown-ups represent 21% of all meningococcal sickness cases in the US and are probably going to emphatically affect the meningococcal immunization market.
The meningococcal antibody market in Europe is being driven by non-benefit associations that give funding to explore projects, medical services proficient preparation, patient data and backing, and request driven by a critical expansion in routine vaccination.
As indicated by the European Place for Illness Counteraction and Control, obtrusive meningococcal sickness (IMD) is the main source of meningitis and septicemia, with an expected 200,000 cases happening every year. The sickness frequently advances quickly with a 8-15% case-casualty proportion. Certain European nations that are planning for a meningococcal immunization program are supporting the meningococcal immunization market.
The Asia-Pacific locale is supposed to show the most elevated CAGR from 2021 to 2030. This is because of the expanded transmission of meningococcal microbes which has brought about a critical expansion in the quantity of clinical projects for the viable improvement of meningococcal immunizations because of capricious events across various age gatherings and nations in the district. This has reinforced the Asia-Pacific meningococcal immunizations market.
Major Players
The prominent players operating in the global meningococcal vaccines market include Pfizer Inc (US), Novartis AG (Switzerland), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Sanofi S.A.(France), and Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Ltd (China), Bio-Manguinhos (Brazil).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.


目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING AWARENESS AND SURGE IN TRAVEL VACCINE

4.2.2 INCREASE IN R&D FOR VACCINE TECHNOLOGY

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY GUIDELINES AND PRODUCT RECALLS

4.4 OPPORTUNITIES

4.4.1 INCREASING INCLUSION IN NATIONAL IMMUNIZATION PROGRAMS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 BARGAINING POWER OF BUYERS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL MENINGOCOCCAL VACCINES MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON PRODUCTION OF MENINGOCOCCAL VACCINE

5.3.4 IMPACT ON KEY PLAYERS

6 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE

6.1 OVERVIEW

6.2 CONJUGATE

6.3 SUBCAPSULAR

6.4 POLYSACCHARIDE

7 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE

7.1 OVERVIEW

7.2 MENACWY

7.3 MENB/BC

7.4 MENC

7.5 MENAC

7.6 MENA

8 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 RESEARCH & ACADEMIC INSTITUTES

8.4 OTHERS

9 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 JAPAN

9.4.2 CHINA

9.4.3 INDIA

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA-PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL

10.6.2 PARTERSHIP/AGREEMENT

10.7 FINANCIAL MATRIX

10.7.1 SALES (USD MILLION), 2021

10.7.2 R&D EXPENDITURE (USD MILLION), 2021

11 COMPANY PROFILES

11.1 PFIZER INC.

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS/SERVICES OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 NOVARTIS AG

11.2.1 COMPANY OVERVIEWS

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS/SERVICES OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 SANOFI S.A.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS/SERVICES OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 SERUM INSTITUTE OF INDIA PVT. LTD.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS/SERVICES OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 GLAXOSMITHKLINE PLC.

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS/SERVICES OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 MERCK & CO., INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 KEY STRATEGIES

11.7 INCEPTA PHARMACEUTICALS LTD.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS/SERVICES OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 BIO-MED

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 WALVAX BIOTECHNOLOGY CO., LTD.

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS/SERVICES OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 BIO-MANGUINHOS

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS/SERVICES OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR CONJUGATE, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR SUBCAPSULAR, BY REGION, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR POLYSACCHARIDE, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL: MENINGOCOCCAL VACCINES MARKET FOR MENACWY, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENB/BC, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENC, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENAC, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENA, BY REGION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL: MENINGOCOCCAL VACCINES MARKET FOR HOSPITALS, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 19 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 20 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 22 US: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 23 US: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 24 US: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 25 CANADA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 26 CANADA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 27 CANADA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 28 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 29 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 30 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 31 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 32 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 33 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 34 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 35 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 36 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 37 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 38 UK: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 39 UK: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 40 UK: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 41 ITALY: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 42 ITALY: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 43 ITALY: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 44 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 45 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 46 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 47 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 48 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 49 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 54 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 55 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 56 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 57 CHINA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 58 CHINA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 59 CHINA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 60 INDIA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 61 INDIA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 62 INDIA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 63 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 64 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 65 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 66 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 67 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 68 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 69 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 70 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 72 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 73 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 74 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 75 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 76 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 77 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 78 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 79 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 80 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 81 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 82 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2030 (USD MILLION)

TABLE 83 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2030 (USD MILLION)

TABLE 84 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 85 MAJOR PLAYERS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

TABLE 86 MOST ACTIVE PLAYER IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

TABLE 87 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 88 PARTERSHIP/AGREEMENT

TABLE 89 PFIZER INC: PRODUCTS/SERVICES OFFERED

TABLE 90 PFIZER INC.: KEY DEVELOPMENTS

TABLE 91 NOVARTIS AG: PRODUCTS/SERVICES OFFERED

TABLE 92 SANOFI S.A.: PRODUCTS/SERVICES OFFERED

TABLE 93 SANOFI S.A.: KEY DEVELOPMENTS

TABLE 94 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS/SERVICES OFFERED

TABLE 95 GLAXOSMITHKLINE PLC.: PRODUCTS/SERVICES OFFERED

TABLE 96 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED

TABLE 97 MERCK & CO., INC.: KEY DEVELOPMENTS

TABLE 98 INCEPTA PHARMACEUTICALS LTD.: PRODUCTS/SERVICES OFFERED

TABLE 99 BIO-MED: PRODUCTS/SERVICES OFFERED

TABLE 100 WALVAX BIOTECHNOLOGY CO., LTD.: PRODUCTS/SERVICES OFFERED

TABLE 101 BIO-MANGUINHOS.: PRODUCTS/SERVICES OFFERED

TABLE 102 BIO-MANGUINHOS.: KEY DEVELOPMENTS


LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL MENINGOCOCCAL VACCINES MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MENINGOCOCCAL VACCINE MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL MENINGOCOCCAL VACCINE MARKET

FIGURE 9 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2021 & 2030 (USD MILLION)

FIGURE 10 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY SEROYYPE, 2021 & 2030 (USD MILLION)

FIGURE 11 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2021 & 2030 (USD MILLION)

FIGURE 12 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY REGION 2020 & 2030 (USD MILLION)

FIGURE 13 GLOBAL: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY REGION, 2021

FIGURE 14 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021

FIGURE 15 EUROPE: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021

FIGURE 16 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021

FIGURE 17 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY REGION 2021

FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

FIGURE 20 GLOBAL MENINGOCOCCAL VACCINES MARKET: COMPETITIVE LANDSCAPE

FIGURE 21 SALES 2021

FIGURE 22 R&D EXPENDITURE, 2021

FIGURE 23 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 PFIZER INC: SWOT ANALYSIS

FIGURE 25 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 NOVARTIS AG: SWOT ANALYSIS

FIGURE 27 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 SANOFI S.A.: SWOT ANALYSIS

FIGURE 29 SERUM INSTITUTE OF INDIA PVT. LTD.: SWOT ANALYSIS

FIGURE 30 GLAXOSMITHKLINE PLC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS

FIGURE 32 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com